Tech Company Financing Transactions
Bexson Biomedical Funding Round
Bexson Biomedical, based in Santa Barbara, received $4.8 million in funding from Noetic Fund and private investors.
Transaction Overview
Company Name
Announced On
2/4/2021
Transaction Type
Venture Equity
Amount
$4,800,000
Round
Series A
Investors
Noetic Fund (Lead Investor)
Proceeds Purpose
The company intends to use the funds to go through pre-clinical and GMP manufacturing scale up for its proprietary ketamine formulation, BB106, and develop a wearable delivery device with medical device manufacturer, Stevanato Group.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
369 Paso Robles Dr.
Santa Barbara, CA 93108
USA
Santa Barbara, CA 93108
USA
Phone
Undisclosed
Website
Email Address
Overview
Bexson Biomedical is developing a unique formulation of ketamine for chronic and acute pain disorders. The opioid crisis is a Public Health Emergency in the United States. There is a desperate need for safe and potent treatments that can offer a real alternative to opioid-based pain management to millions of people in pain.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gregg Peterson
Chief Scientific Officer
Jeffrey Becker
Vice President
Sheldon Moberg
VP - R & D
Mark Wiederhold
Browse more venture capital transactions:
Prev: 2/4/2021: WorkStep venture capital transaction
Next: 2/4/2021: Rightfoot venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs